TRAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
First Tracks Biotherapeutics Inc (TRAX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company has strong analyst support, a promising lead drug in development, and significant upside potential. Despite the lack of technical and options data, the positive catalysts outweigh the negatives, making it a suitable long-term investment.
No data available for trend analysis. The stock is in pre-market trading at $18.97.
Strong analyst ratings with Overweight/Buy ratings and price targets ranging from $31 to $
Promising lead drug ANB033 with potential blockbuster sales and clinical de-risking.
Recent NASDAQ debut with $180 million in cash to support therapeutic development.
Spin-off from AnaptysBio, enhancing shareholder value.
Lack of historical trading trends and technical data.
No recent hedge fund or insider trading activity to indicate strong institutional interest.
No financial data available for analysis due to error in data retrieval.
Analysts from JPMorgan, Barclays, and UBS have initiated coverage with Overweight/Buy ratings and price targets ranging from $31 to $45, citing significant upside potential for the lead drug ANB033 in autoimmune diseases.
